In the 3 permissive models treated with SVV-GFP for 48 h, effective infection was observed in the CD133+/CD15+ cells, resulting in 30.7% positivity in IC-K012GBM, 49.7% in the IC-K031GBM and up to 66% in the IC-A46GBM (P < 0.05; Fig. 4a, c); whereas in the resistant tumors (IC-K035GBM), less than 5% SVV-GFP positivity was observed (P < 0.05; Fig. 4a–c) regardless of the expression status of CSC markers. This evidence concerns the gene PROM1 and infection.